Machine signal
Active cluster sell — 3 distinct insiders, $3.2M, window ends Jul 10, 2026.
Figures computed from official regulatory filings — .
Analysttarget 39.91 USD (+63%) · consensus 4.69/5 · 11 buy · 2 hold · 0 sell
Ownershipinsiders 28.8% · institutions 74.91% · short 17.7% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Arcus Biosciences, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases; and Bristol-Myers Squibb Company to develop a novel treatment regimen that delivers tumor control in kidney cancer. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.
Market information source · Oct 5, 2026
SEC company identity · Oct 5, 2026
Open-market timeline · full history
49 buys151 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| Azoy Alexander | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Azoy Alexander | Exercise | $43.6K | SEC |
| Azoy Alexander | Sell | $84.8K | SEC |
| Jaen Juan C.track record | Sell | $566.4K | SEC |
| Jaen Juan C.track record | Sell | $1.5M | Unusual size | SEC |
| Jaen Juan C.track record | Sell | $7.9K | SEC |
| Jaen Juan C.track record | Sell | $249.7K | SEC |
| Jaen Juan C.track record | Sell | $190.7K | SEC |
| Jaen Juan C.track record | Sell | $389.5K | SEC |
| Jaen Juan C.track record | Sell | $47.6K | SEC |
| Lambert Nicole | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Ribas Antoni | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Lacey David L. | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Tang Carolyn C. | ExerciseD (derivative) | $87.7K | SEC |
| Lacey David L. | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Tang Carolyn C. | Exercise | $87.7K | SEC |
| FALBERG KATHRYN Etrack record | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| PERLMAN ANDREW J | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| KANEKO YASUNORItrack record | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Machado Clarence Patricktrack record | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Machado Clarence Patricktrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| FALBERG KATHRYN Etrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Lambert Nicole | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| PERLMAN ANDREW J | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Ribas Antoni | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |